Name: EDS and Narcolepsy Treatment Options
Uploaded: 2023-05-10T13:02:00.000Z
Description: Neurology experts discuss excessive daytime sleepiness (EDS) and narcolepsy treatment options.

Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Disease Spotlight

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending Aprl 12, 2024. 

NeurologyLive® Friday 5 — April 12, 2024

Videos

The director of the Brain Health Imaging Institute in the department of radiology at Weill Cornell Medicine talked about using a novel radiotracer to understand the movement of fluids and waste products in the brain. [WATCH TIME: 5 minutes]

Utilizing a Radiotracer to Shed Light on Brain Fluid Dynamics: Mony de Leon, EdD

ALKS 2680, an investigational orexin 2 receptor agonist, showed promise for improving sleep latency in patients with narcolepsy type 2 and idiopathic hypersomnia in a phase 1b study.

ALKS 2680 Significantly Improves Wakefulness for Narcolepsy Type 2 and Idiopathic Hypersomnia in Phase 1b Trial

Analyzing data from the H70-BCS, researchers identified around 6.2% of 70-year-olds meeting lecanemab treatment criteria, suggesting millions in Europe and the US might be eligible.

Population-Based Study Reveals Low Eligibility Rates for Alzheimer Therapy Lecanemab

, has been with the team since September 2022. Follow her on Twitter 

The executive vice president and chief research officer of the Muscular Dystrophy Association shared her reaction to the recent FDA approval of givinostat for Duchenne muscular dystrophy.

NeuroVoices: Sharon Hesterlee, PhD, on Givinostat’s Approval for Duchenne Muscular Dystrophy, Future Prospects

Manager of Health Literacy at National MS Society.

Elizabeth Miller, MA, the manager of health literacy at the National MS Society, discussed the impact of health literacy in the multiple sclerosis community. 

Advancing Equity and Inclusion: Health Literacy for the MS Community and Beyond

The chief of neurology and co-director of the Neurological Institute at the Children’s Hospital Los Angeles provided insight on the barriers to prevent neurodevelopmental disorders and the lack of currently validated biomarkers. [WATCH TIME: 4 minutes]

Challenges in Identifying Markers for Neurodevelopmental Disorders: Shafali Jeste, MD

, has been with the team since October 2019. Follow him on Twitter 

Advancements in the detection and care of multiple sclerosis have led to improved diagnosis rates and a more multidisciplinary approach to treating the autoimmune disorder.

Diagnosing, Treating, and Preventing Multiple Sclerosis: Marcus Institute Gold Standard Center

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

Twitter

LinkedIN

YouTube

Spotlight

AAN 2024

MDA 2024

ACTRIMS 2024

Treating NMOSD: What's Next?

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

1rem

View

Advances in the Management of Excessive Daytime Sleepiness and Narcolepsy

In this program, sleep experts will discuss the importance of timely and accurate diagnosis, recent approvals and available treatment options for the management of narcolepsy and excessive daytime sleepiness.

Experts provide an overview of excessive daytime sleepiness and narcolepsy.

Narcolepsy  Overview 

Anne Marie Morse, DO, FAASM, discusses the burden and risk factors associated with excessive daytime sleepiness and narcolepsy.

Burden and Risk Factor of Narcolepsy

Experts discuss narcolepsy diagnosis and the challenges associated with it.

Diagnosis of Narcolepsy

Thomas E. Scammell, MD, discusses evaluating excessive daytime sleepiness (EDS).

EDS Evaluation 

Debra Stultz, MD, provides an overview of the available resources that are available for narcolepsy treatment.

Available Resources for Narcolepsy Treatment

Neurology experts describe the goals of therapy for narcolepsy treatment. 

Goals of Therapy for Narcolepsy 

Karl Doghramji, MD, FAASM, DFAPA, provides an overview of the pharmacological treatment options for narcolepsy.

Pharmacological Treatment Options for Narcolepsy

Neurology experts discuss excessive daytime sleepiness (EDS) and narcolepsy treatment options. 

EDS and Narcolepsy Treatment Options

Thomas E. Scammell, MD, provides an overview of the mechanism of action of pitolisant for the treatment of narcolepsy.

Pitolisant: Mechanism of Action

Anne Marie Morse, DO, FAASM, discusses the efficacy and safety profile of pitolisant for the treatment of narcolepsy.

Pitolisant Efficacy and Safety

Experts discuss the efficacy and safety profile of solriamfetol for the treatment of narcolepsy.

Solriamfetol Efficacy and Safety

Experts discuss sodium oxybate and antidepressants for treatment of cataplexy.

Sodium Oxybate and Antidepressants for Treatment of Cataplexy 

Neurology experts discuss the unmet needs in narcolepsy treatment and share clinical pearls from their experiences. 

Unmet Needs in Narcolepsy and Clinical Pearls

Peer Exchange

Clinical

 Peer Exchange video series features panels of expert physicians engaging in in-depth discussions about practice-changing treatments, challenges in care, and the future paradigm of management for neurologic diseases.

EDS and Narcolepsy Treatment Options

EP: 1.Narcolepsy Overview

EP: 2.Burden and Risk Factor of Narcolepsy

EP: 3.Diagnosis of Narcolepsy

EP: 4.EDS Evaluation

EP: 5.Available Resources for Narcolepsy Treatment

EP: 6.Goals of Therapy for Narcolepsy

EP: 7.Pharmacological Treatment Options for Narcolepsy

EP: 8.EDS and Narcolepsy Treatment Options

EP: 9.Pitolisant: Mechanism of Action

EP: 10.Pitolisant Efficacy and Safety

EP: 11.Solriamfetol Efficacy and Safety

EP: 12.Sodium Oxybate and Antidepressants for Treatment of Cataplexy

EP: 13.Unmet Needs in Narcolepsy and Clinical Pearls